Fundraising FoxNiKang Therapeutics
Wilmington, CN · Founded 2017 · 10 known investors
Find your way into NiKang Therapeutics
Sign up to see every warm intro you have to NiKang Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NiKang Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2. It focuses on precision medicine for difficult-to-drug oncology targets, with three compounds advanced into first-in-human clinical testing.
Founders & leadership
NiKang Therapeutics was founded in 2017 by Yan Lou and Zhenhai Gao.
Board
Investors · 10
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · Not right? Tell us
How we know: The Innovation Space's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$200M disclosed across 1 round · 2021
▶$200MraisedJun 2021 · 30 investors · BiotechnologyRule 506(b)
- Gary YeungDirector
- Ting JiaDirector
- Hong (Kelsey) ChenExecutive Officer
- Zhenhai GaoExecutive Officer, Director
- Roderick WongDirector
- Wei FuDirector
- Zhengbin YaoDirector
- Sean CaoDirector
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as NiKang Therapeutics.
Frequently asked questions
- What does NiKang Therapeutics do?
- NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2. It focuses on precision medicine for difficult-to-drug oncology targets, with three compounds advanced into first-in-human clinical testing.
- Who founded NiKang Therapeutics?
- NiKang Therapeutics was founded by Yan Lou, Zhenhai Gao in 2017.
- Who are NiKang Therapeutics's investors?
- NiKang Therapeutics's investors include EcoR1 Capital, HBM Healthcare Investments, HBM Partners, LAV, Lilly Asia Ventures, RA Capital, Samsara BioCapital, The Innovation Space and 2 more.
- How much funding has NiKang Therapeutics raised?
- NiKang Therapeutics has disclosed $200M raised across 1 round.
- Where is NiKang Therapeutics headquartered?
- NiKang Therapeutics is headquartered in Wilmington, CN.